Preliminary study of efficacy and safety of Pembrolizumab and Nivolumab in treatment of advanced malignant tumors
Hou Lina1,Dina·Suolitiken2,Ren Hua3,4
1Medical abministration department,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China; 2Department of Internal Medicine-Oncology,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China; 3Department of Radiation Oncology,National Cancer Center,National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China; 4Department of Radiation Oncology,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China
Abstract：Objective To preliminarily compare the efficacy and safety of Pembrolizumab and Nivolumab in the treatment of advanced malignant tumors. Methods Clinical data of 50 patients diagnosed with advanced malignant tumors treated with Pembrolizumab and Nivolumab from January 2017 to August 2018 in our hospital were retrospectively analyzed. All patients were divided into the Pembrolizumab (n=26) and Nivolumab groups (n=24). The incidence of adverse reactions was statistically compared between two groups by using χ2 test. The survival analysis was performed by using Kaplan-Meier method. Results The median progression-free survival in the Pembrolizumab group was 213 d, and 146 d in the Nivolumab group (P>0.05). The incidence of aminotransferase elevation and hypothyroidism in the Nivolumab group was significantly higher than that in the Pembrolizumab group (63% vs. 23%,12% vs. 0%, both P<0.05), whereas the incidence of oral mucositis in the Nivolumab group was 0%, significantly lower than 15% in the Pembrolizumab group (P<0.05). The median overall survival time in the Pembrolizumab group was 579d, and 238 d in the Nivolumab group (P>0.05). Conclusion Clinical efficacy does not significantly differ, whereas the incidence of adverse reactions slightly differs between the Pembrolizumab and Nivolumab groups.
Hou Lina,Dina·Suolitiken,Ren Hua. Preliminary study of efficacy and safety of Pembrolizumab and Nivolumab in treatment of advanced malignant tumors[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 687-691.
[1] Francisco LM,Sage PT,Sharpe AH. The PD-1 pathway in tolerance and autoimmunity[J]. Immunol Rev,2010,236(1):219-242. DOI:10.1111/j.1600-065X.2010.00923.x. [2] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nature Rev Cancer,2012,12(4):252-264. DOI:10.1038/nrc3239. [3] Iwai Y,Ishida M,Tanaka Y,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proc Natl Acad Sci USa,2002,99(19):12293-12297. DOI:10.1073/pnas.192461099. [4] Brahmer J,Reckamp KL,Baas P,et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med,2015,373(2):123-135. DOI:10.1056/NEJMoa1504627. [5] Robert C,Long GV,Brady B,et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med,2015,372(4):320-330. DOI:10.1056/NEJMoa1412082. [6] Gettinger S,Rizvi NA,Chow L Q,et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol,2016,34(25):2980-2987. DOI:10.1200/JCO.2016.66.9929. [7] Gettinger S,Horn L,Jackman D,et al. Five-year follow-Up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J]. J Clin Oncol,2018,36(17):1675-1684. DOI:10.1200/JCO.2017.77.0412. [8] Topalian SL,Sznol M,Mcdermott DF,et al. Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol,2014,32(10):1020-1030. DOI:10.1200/JCO.2013.53.0105. [9] Haanen J,Carbonnel F,Robert C,et al. Management of Toxicities From Immunotherapy:ESMO Clinical Practice Guidelines for Diagnosis,Treatment and Follow-Up[J]. Ann Oncol,2017,28(suppl_4):v119-v142.10.1093/annonc/mdx225. [10] Brahmer JR,Lacchetti C,Schneider BJ,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol,2018,36(17):1714-1768. DOI:10.1200/JCO.2017.77.6385. [11] Roger A,Finet A,Boru B,et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients[J]. Oncoimmunology,2018,7(7):e1442166. DOI:10.1080/2162402X.2018.1442166. [12] Sun D,Ma J,Wang J,et al. Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer:a real-world study in Chinese Cohort[J]. Ther Clin Risk Manag,2018,14:1691-1700. DOI:10.2147/TCRM. S173041. [13] De Lima LG,Wu YL,Sadowski S,et al. P2.43:pembrolizumab vs. platinum-based chemotherapy for PD-L1+ NSCLC:phase 3,randomized,open-label. KEYNOTE-042(NCT02220894):track:immunotherapy[J]. J Thorac Oncol,2016,11(10S):S244-S245. DOI:10.1016/j.jtho.2016.08.114. [14] Ma W,Gilligan BM,Yuan J,et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J]. J Hematol Oncol,2016,9(1):47. DOI:10.1186/s13045-016-0277-y. [15] Topalian SL,Taube JM,Anders RA,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer,2016,16(5):275-287. DOI:10.1038/nrc.2016.36. [16] Kyi C,Postow MA. Immune checkpoint inhibitor combinations in solid tumors:opportunities and challenges[J]. Immunotherapy,2016,8(7):821-837. DOI:10.2217/imt-2016-0002. [17] Xu C,Chen Y,Du X,et al. Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis[J]. BMJ,2018:k4226. DOI:10.1136/bmj.k4226. [18] Naidoo J,Page DB,Li BT,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol,2015,26(12):2375-2391. DOI:10.1093/annonc/mdv383. [19] Heinzerling L,Ott PA,Hodi FS,et al. Cardiotoxicity associated with CTLA4 and PD1 blocking Immunotheiapy[J]. J ImmunoTher Cancer,2016,4(1). DOI:10.1186/s40425-016-0152-y.
2019, Vol. 28 
